- Home
- AVNW vs CUE Comparison
AVNW vs CUE Comparison
Compare AVNW & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVNW | CUE |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.2M | 233.5M |
| IPO Year | 2007 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AVNW | CUE |
|---|---|---|
| Price | $19.85 | $31.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $34.50 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 190.9K | 149.3K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.00 | 61.11 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $243,858,000.00 | $27,466,000.00 |
| Revenue This Year | $5.59 | N/A |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | $109.11 | ★ N/A |
| Revenue Growth | 0.56 | ★ 195.75 |
| 52 Week Low | $13.92 | $0.17 |
| 52 Week High | $27.02 | $45.50 |
Technical Indicators
Market Signals| Indicator | AVNW | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 55.68 |
| Support Level | $18.99 | $24.35 |
| Resistance Level | $23.04 | $32.50 |
| Average True Range (ATR) | 1.16 | 3.03 |
| MACD | -0.01 | 0.40 |
| Stochastic Oscillator | 22.43 | 81.89 |
Price Performance
Historical ComparisonAbout AVNW Aviat Networks Inc.
Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.